Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Argent Biopharma ( (AU:RGT) ) has shared an update.
Argent Biopharma Ltd has achieved a significant milestone by commencing the formal supply of EU-GMP cannabinoid-based active pharmaceutical ingredients to the University Medical Centre Ljubljana for the treatment of drug-resistant epilepsy. This transition from pilot to routine hospital use marks a new commercial opportunity for the company in the EU market. Additionally, CannEpil® has gained approval for prescription in Germany, reinforcing Argent’s European expansion strategy and acceptance of cannabinoid-based medicine for CNS disorders. Strategic agreements with AusCann and David Trading Ltd further enhance Argent’s operational capabilities and market reach.
More about Argent Biopharma
Argent Biopharma Ltd is a company in the biopharmaceutical industry, focusing on cannabinoid-based therapies. Its primary products include CannEpil®, a cannabinoid-derived drug for refractory epilepsy. The company is actively involved in the European market, with a focus on expanding its presence and regulatory engagement in the EU and U.S.
Average Trading Volume: 39,751
Technical Sentiment Signal: Sell
Current Market Cap: A$4.82M
For detailed information about RGT stock, go to TipRanks’ Stock Analysis page.